Piperazine Ring In The Nitrogen Containing Substituent Patents (Class 544/44)
-
Publication number: 20140294994Abstract: The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and/or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and/or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.Type: ApplicationFiled: October 29, 2012Publication date: October 2, 2014Inventor: Ch-Ying Huang
-
Publication number: 20130310348Abstract: This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQR and CQS malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQR reversal moiety. Exemplary RCQ chemical structures are provided. Also provided are pharmaceutical compositions including the disclosed RCQ compounds, and methods of using such compounds and compositions for the treatment of malaria and inhibition of CQR or CQS Plasmodium sp. (such as P. falciparum).Type: ApplicationFiled: July 25, 2013Publication date: November 21, 2013Applicants: State UniversityInventors: David H. Peyton, Steven Burgess
-
Patent number: 8501920Abstract: The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides compositions comprising mini-dystrophin peptides, and methods for expressing mini-dystrophin peptides in target cells.Type: GrantFiled: July 3, 2007Date of Patent: August 6, 2013Assignee: The Regents of The University of MichiganInventors: Jeffrey S. Chamberlain, Scott Q. Harper
-
Publication number: 20130184268Abstract: The invention relates to 2-(R2-thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine according to general formula I, for treating a ?-amyloidopathy or an ?-synucleinopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter. The invention also relates to a method for the diagnosis or prediagnosis of a ?-amyloidopathy or an ?-synucleopathy accompanied by a cerebral protein deposit and a reduced activity of the cerebral ABCC1-transporter, or for determining the risk of a proband suffering from such an illness, the proband already having accumulated substances transported by the cerebral ABCC1 transporter.Type: ApplicationFiled: August 30, 2011Publication date: July 18, 2013Applicant: Immungenetics AGInventor: Jens Pahnke
-
Patent number: 8460696Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: GrantFiled: March 19, 2010Date of Patent: June 11, 2013Assignee: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Patent number: 8377929Abstract: Novel crystalline form of perphenazine 4-aminobutyrate trimesylate and a process of producing the same are disclosed. The novel crystalline form is characterized by a unique XRPD pattern and a DSC that exhibits an endothermic peak at a relatively high temperature (e.g., higher than 209° C.). Also disclosed are a process of preparing perphenazine 4-aminobutyrate trimesylate by in situ deprotection and salification, in a single-step synthesis, and a highly pure perphenazine 4-aminobutyrate trimesylate obtained thereby. Uses of any of the described perphenazine 4-aminobutyrate trimesylate are also disclosed.Type: GrantFiled: February 24, 2011Date of Patent: February 19, 2013Assignees: Ramot at Tel-Aviv University Ltd., Bar-Ilan University, BioLineRX Ltd.Inventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman, Mazal Shaul, Efrat Halbfinger
-
Patent number: 8168628Abstract: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.Type: GrantFiled: April 21, 2010Date of Patent: May 1, 2012Assignees: Ramot at Tel-Aviv University Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Publication number: 20120035161Abstract: The invention includes compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, treating diseases associated with activated lymphocytes, or treating PAH.Type: ApplicationFiled: July 18, 2011Publication date: February 9, 2012Inventors: Stephen Roth, Bruce Tomczuk
-
Publication number: 20110223221Abstract: The present invention relates to processes of stabilization of cation radicals from one or more phenothiazinic compounds or derivatived compounds thereof. Another embodiment of the present invention relates to cosmeceutical formulations comprising one or more phenothiazinic compounds or derivatived compounds thereof, in combination with cosmeceutically acceptable excipients. The invention also relates to uses of one or more phenothiazinic compounds or derivatived compounds thereof, i the preparation of cosmeceutical formulations for the prevention of skin diseases and disturbances. Methods for prevention of skin diseases and disturbances are also disclosed by the present invention. Particularly, the embodiments of the present invention employ the cited one or more phenothiazinic compounds o derivatived compounds thereof in the form of their stabilized cation radicals.Type: ApplicationFiled: May 12, 2009Publication date: September 15, 2011Inventors: Iseli Lourenco Nantes, Tiago Rodrigues, Carolina Gregorutti Dos Santos
-
Patent number: 7981885Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.Type: GrantFiled: August 31, 2007Date of Patent: July 19, 2011Assignee: Immune Control Inc.Inventors: Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
-
Patent number: 7838671Abstract: A new nitrogen-containing organosilicon compound contains tertiary amine groups and carbonyl groups wherein the tertiary amine groups are selected from R1R2N— (where R1 and R2 are the same or different univalent hydrocarbon groups of 1-15 carbon atoms), alicyclic amino groups, or heterocyclic amino groups containing in their rings one or more tertiary amine groups.Type: GrantFiled: December 10, 2007Date of Patent: November 23, 2010Assignee: Dow Corning Toray Company, Ltd.Inventors: Makoto Iwai, Mitsuyoshi Hamada
-
Publication number: 20100189762Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: ApplicationFiled: December 21, 2009Publication date: July 29, 2010Applicant: EMORY UNIVERSITYInventor: Jack L. Arbiser
-
Publication number: 20100159596Abstract: Methods and small molecule compounds for stem cell differentiation are provided.Type: ApplicationFiled: September 16, 2009Publication date: June 24, 2010Applicants: Burnham Institute for Medical Research, Human BioMolecular Research InstituteInventors: Mark Mercola, Marcia Dawson, John Cashman
-
Publication number: 20100120755Abstract: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.Type: ApplicationFiled: January 14, 2010Publication date: May 13, 2010Applicants: Ramot At Tel Aviv University Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Publication number: 20100099666Abstract: The present invention relates to new phenothiazine modulators of H1 receptors and/or D2 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: October 20, 2009Publication date: April 22, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7598239Abstract: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.Type: GrantFiled: December 27, 2007Date of Patent: October 6, 2009Assignees: Ramot At Tel Aviv University Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Patent number: 7544681Abstract: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.Type: GrantFiled: March 25, 2004Date of Patent: June 9, 2009Assignees: Ramot At Tel Aviv University Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Patent number: 7491537Abstract: A nucleic acid formulation for use in gene delivery comprising a nucleic acid and an anionic polymer is disclosed. Examples of the anionic polymer includes anionic amino acid polymer or poly-amino acid (such as poly-L-glutamic acid, poly-D-glutamic acid, poly-L-aspartic acid, poly-D-aspartic acid), poly-acrylic acid, polynucleotides, poly galacturonic acid, and poly vinyl sulfate.Type: GrantFiled: November 20, 2006Date of Patent: February 17, 2009Assignee: Genetronics Biomedical CorporationInventors: Jason G Fewell, Fiona MacLaughlin, Louis C Smith, Francois Nicol, Alain Rolland
-
Patent number: 7053085Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.Type: GrantFiled: March 10, 2004Date of Patent: May 30, 2006Assignee: Merck & Co. Inc.Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
-
Patent number: 6992082Abstract: Phenothiazine derivatives of formula (I) are disclosed. The compounds are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.Type: GrantFiled: January 18, 2002Date of Patent: January 31, 2006Assignee: Cytokinetics, Inc.Inventors: Jeffrey T. Finer, John C. Chabala
-
Patent number: 6800618Abstract: A compound having the structural formula or a pharmaceutically acceptable salt or prodrug thereof, wherein X is a substituted or unsubstituted alkyl or a heteroatom; n is 4, 5 or 6; Y is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or wherein R1 and R2 are each independently, H, a heteroatom, substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and wherein each ring structure are independently substituted or unsubstituted is disclosed. Also disclosed are chemosensitizing agents and methods of modulating, attenuating, reversing, or affecting a cell's or organism's resistance to a given drug such as an antimalarial.Type: GrantFiled: May 7, 2001Date of Patent: October 5, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Ai J. Lin, Jian Guan, Dennis E. Kyle, Wilbur K. Milhous
-
Publication number: 20040072825Abstract: The present invention relates to the compound 2-(2-(4-((2R)-2-methyl-3-(10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethoxy)ethanol, and its pharmaceutically acceptable salts, as well as to processes for the preparation thereof. It also relates to pharmaceutical compositions containing the said compounds, as well as to therapeutic uses thereof.Type: ApplicationFiled: November 5, 2003Publication date: April 15, 2004Inventors: Yves Lamberty, Jacques Timmermans, Tony Waegemans, Guy Bodson, Febienne Broeders
-
Publication number: 20030187254Abstract: Acetyl Coenzyme A Carboxylase inhibitors, pharmaceutical compositions containing such compounds and the use of such compounds to treat for example, Metabolic Syndrome including atherosclerosis, diabetes and obesity.Type: ApplicationFiled: February 20, 2003Publication date: October 2, 2003Applicant: Pfizer Inc.Inventors: David A. Perry, H. James Harwood
-
Patent number: 6583138Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.Type: GrantFiled: January 4, 2001Date of Patent: June 24, 2003Assignee: Eisai Co., Ltd.Inventors: Mitsuaki Miyamoto, Tatsuya Yoshiuchi, Keizo Sato, Motohiro Soejima, Takashi Sato, Koichi Kikuchi, Hiroyuki Yoshimura, Katsuhiro Moriya, Yoshinori Sakuma, Shigeru Akasofu, Koji Yamada
-
Patent number: 6407231Abstract: This invention relates to a novel, technically advantageous process for the preparation of a mixture of alkylated phenothiazines and diphenylamines. Starting from diphenylamine, this is reacted with elemental sulfur in the presence of iodine, and the substance mixture of diphenylamine and phenothiazine is treated with an olefin in the presence of an acid catalyst.Type: GrantFiled: July 5, 2000Date of Patent: June 18, 2002Assignee: Ciba Specialty Chemicals CorporationInventors: Samuel Evans, Stephan Allenbach, Paul Dubs
-
Patent number: 6333322Abstract: A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by formula (I) effective against diseases in which histamine, leukotrienes, etc. participate and effective in preventing or treating diseases in which chemical mediators such as histamine and leukotrienes participate, for example, asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, gastrointestinal allergy and food allergy.Type: GrantFiled: September 21, 1998Date of Patent: December 25, 2001Assignee: Eisai Co., Ltd.Inventors: Mitsuaki Miyamoto, Tatsuya Yoshiuchi, Keizo Sato, Makoto Kaino, Masayuki Tanaka, Motohiro Soejima, Katsuhiro Moriya, Yoshinori Sakuma, Koji Yamada, Kokichi Harada, Yukio Nishizawa, Seiichi Kobayashi, Makoto Okita, Koichi Katayama
-
Patent number: 6159966Abstract: A compound of formula (I) ##STR1## its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates, wherein R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are the same or different; R.sup.1 and R.sup.2 together represent along with carbon atoms to which they are attached an aromatic cyclic structure containing 5-6 ring atoms which may optionally be substituted; X represents a heteroatom selected from oxygen or sulfur; R.sup.7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl group or optionally substituted aralkyl group or forms a bond together with R.sup.8 ; R.sup.8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl group or optionally substituted aralkyl or R.sup.8 forms a bond together with R.sup.Type: GrantFiled: August 14, 1998Date of Patent: December 12, 2000Assignees: Reddy-Cheminor Inc., Dr. Reddy's Research FoundationInventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Ashok Chennaveerappa Bajji, Shivaramayya Kalchar, Sekar Reddy Alla, Rajagopalan Ramanujam, Reeba Kannimel Vikramadithyan
-
Patent number: 6147084Abstract: The present invention relates to a novel brain cell protective agent having for its active ingredient a morphinan derivative represented with Compound 1 ##STR1## or pharmacologically acceptable acid addition salt thereof. The compounds used in the present invention were found to have excellent defensive effects against brain nerve cell necrosis in both in vitro and in vivo pharmacological evaluations, and can be used as useful preventive and therapeutic agents of ischemic brain disorders, brain nerve cell disorders and dementia.Type: GrantFiled: March 4, 1999Date of Patent: November 14, 2000Assignee: Toray Industries, Inc.Inventors: Hiroshi Nagase, Yoshifumi Imamura, Takashi Endo, Susumu Matsuda, Yasushi Miyauchi
-
Patent number: 4985419Abstract: Phenothiazine derivatives of formula: ##STR1## in which Y is hydrogen or halogen, R.sub.1 and R.sub.2, which may be identical or different, denote alkyl, cycloalkyl-alkyl, hydroxyalkyl or acetyloxyalkyl radicals or form, together with the nitrogen atom to which they are attached, an optionally substituted, saturated or partially unsaturated 4- to 7-membered heterocycle; and either X is oxygen, sulphur or: N-R.sub.4, R is cycloalkyl, phenyl or --CH.sub.2 R.sub.3, R.sub.3 is H, alkyl (1 to 5 C), alkenyl or alkynyl (2 to 4 C), cycloalkyl (3 to 6 C), phenyl, substituted phenyl or a heterocyclic radical, R.sub.4 is H or --CN, except that X is not oxygen if, simultaneously, R.sub.3 is H or alkyl, R.sub.1 and R.sub.2 are alkyl or NR.sub.1 R.sub.2 forms an unsubstituted heterocycle, and Y is H; or X is: N-R.sub.4 and R.sub.Type: GrantFiled: June 12, 1989Date of Patent: January 15, 1991Assignee: Rhone-Poulenc SanteInventors: Claude Garret, Claude Guyon, Bernard Plau, Gerard Taurand
-
Patent number: 4767764Abstract: Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines have opioid antagonist, and/or appetite-controlling properties. Preferred compounds are kappa receptor selective antagonists. Examples of such preferred compounds are 5-Methoxymethyl-3-n-propyl- 1,2,3,4,5,6,7,7a-octahydro-4a,7-ethanobenzofuro[3,2-e]isoquinolin-9-ol and 3-Cyclopropylmethyl-5-methoxymethyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano benzofuro[3,2-e]isoquinoline-9-ol.Type: GrantFiled: May 27, 1986Date of Patent: August 30, 1988Assignee: E. I. Du Pont de Nemours and CompanyInventor: Engelbert Ciganek
-
Patent number: 4705854Abstract: The present invention relates to compounds of the formula (I): ##STR1## or a salt, ester or amide thereof; wherein R.sup.1 is a C.sub.1-7 bivalent aliphatic hydrocarbon group or a single bond;R.sub.2 and R.sub.3 are the same or different and are each hydrogen, C.sub.1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members;R.sup.4 is hydrogen, halogen, C.sub.1-4 alkoxy, C.sub.1-4 alkyl optionally substituted by one to three halogen atoms; or a group R.sub.1 CO.sub.2 H as hereinbefore defined; andA is C.sub.1-4 alkylene or ANR.sub.2 R.sub.3 forms a group --CH.sub.2 --(CH.sub.2).sub.2 or CH.sub.2 --(CH.sub.2).sub.2B is an acidic group other than a mono-carboxylic acid group of comparable or greater acid strength than a carboxylic acid group in a similar chemical environment, provided that any sulphonamide group contains at least one N-H bond.Type: GrantFiled: May 28, 1985Date of Patent: November 10, 1987Assignee: Burroughs Wellcome Co.Inventor: Harry J. Leighton
-
Patent number: 4628087Abstract: Process for the preparation of pharmacologically active compounds containing a sulfoxide group by oxidation of a thioether with hypochlorite in an alkaline medium at a pH higher than 10 and at a temperature comprised between 0.degree. and 40.degree. C.Type: GrantFiled: May 7, 1984Date of Patent: December 9, 1986Assignee: Zambon S.p.A.Inventor: Mariano Meneghin
-
Patent number: 4435393Abstract: Compounds of the general formula: ##STR1## in which either X represents an atom of sulfur and Y represents the N-oxide group or X represents the sulfinyl group or the sulfonyl group and Y represents an atom of nitrogen or the N-oxide group and their salts of addition with mineral or organic acids, their process of preparation and their use as a medicament for the treatment of gastric and duodenal ulcers.Type: GrantFiled: March 22, 1982Date of Patent: March 6, 1984Assignee: PharmindustrieInventors: Marie-Christine Dubroeucq, Jean E. M. A. Rataud
-
Patent number: 4155874Abstract: A new group of compounds, generically classed as phenothiazinyl sulfides, are described having the formula: ##STR1## wherein n is 1 or 2, x and/or y and/or z represent 0, 1 or 2; R.sub.1 may be H, alkyl, aryl, alkaryl, acyl, haloacyl and biologically activating aminoalkyl groups known in the medicinal arts, such as --(CH.sub.2).sub.3 --N(CH.sub.3).sub.2, ##STR2## and -[2-(1-methyl-2-piperidyl)ethyl]; and R.sub.2 and/or R.sub.3 and/or R.sub.4 and/or R.sub.5 and/or R.sub.6 and/or R.sub.7 represent H, OH, Cl, Br, F, CF.sub.3, SH, NO.sub.2, CN, COOH, alkyl, alkoxy, sulfamoyl, dimethylsulfamoyl, dimethyl amino, aryl, alkaryl, acyl, aryloxy, methyl sulfonyl, methyl thio, and -S-phenothiazinyl substitutents; and as charge-transfer complexes of iodine therewith in which the number of moles of iodine associated with the molecule equals 1.5 (range 0.75 to 3.0) times the number of phenothiazinyl groups in the molecule.Methods for the preparation of the compounds are described.Type: GrantFiled: July 28, 1977Date of Patent: May 22, 1979Assignee: West Laboratories, Inc.Inventors: Edward A. Nodiff, Abraham Cantor
-
Patent number: 4153694Abstract: The present invention relates to novel behenic acid esters of the following general formula: ##STR1## wherein X is "N" or "CH," the non-toxic acid addition salts thereof, a method for the preparation of said esters and therapeutic compositions thereof having prolonged effect.It is an object of the present invention to provide behenic acid esters of Formula I, a method of making the same, a method for the alleviation, palliation, mitigation or inhibition of the manifestations of certain physiological-psychological abnormalities of animals therewith, and pharmaceutical compositions comprising such compounds as active ingredient.Other objects will be apparent to one skilled in the art and still other objects will become apparent hereinafter.Type: GrantFiled: August 19, 1977Date of Patent: May 8, 1979Assignee: Kefalas A/SInventors: Jorn L. M. Buus, Niels Lassen
-
Patent number: RE42562Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.Type: GrantFiled: April 26, 2007Date of Patent: July 19, 2011Assignee: Merck Frosst CanadaInventors: Xavier Billot, John Colucci, Robert N. Young, Yongxin Han, Marie-Claire Wilson